Murlentamab GM102: The Innovative Therapeutic in Trial Study Murulentumab GM102 represents a innovative strategy for managing advanced numerous myeloma . This humanized specific molecule selectively interacts BCMA receptor expressed on tumor cells, triggering antibody-dependent cytotoxic killing. Early trial results demonstrate preliminary